Michael E. Wechsler, MD and Jonathan Corren, MD, discuss the clinical differentiation of asthma subgroups and the characterization of inflammatory pathways, as well as biomarkers for severe asthma and their application to clinical practice. They review the latest treatment options, focusing on new biologic-based targeted therapies, differentiating between biologic agents and their mechanism of action, as well as the latest safety and efficacy data of targeted therapy. They also discuss optimal treatment regimens based on asthma severity and biomarkers.

Target Audience

This activity was developed for pulmonologists, allergists, primary care physicians, nurses, nurse practitioners, and other clinicians involved in the management of severe asthma.
Enter your information to begin.

Content Areas

  • New biologic targeted therapies
  • Optimal treatment regimens
  • Potential of combination therapy
  • Biomarkers
  • Novel emerging therapies

faculty

Jonathan Corren, MD
Clinical Associate Professor of Medicine and Pediatrics
Divisions of Clinical Immunology and Allergy
David Geffen School of Medicine at UCLA
Los Angeles, California
Michael Wechsler, MD
Professor of Medicine
Director, NJH Cohen Family Asthma Institute
Department of Medicine
National Jewish Health
Denver, Colorado

Cme credit

Available Credit: 1.00 AMA PRA Category 1 Credit™.
1.00 ACPE Contact Hour
1.00 AANP Contact Hour
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour
Opens: December 31, 2018
Expires: December 30, 2019
Target Audience: Pulmonologists
Allergists
Primary Care Physicians
Nurses
Nurse Practitioners
Other Health Care Providers
This activity is supported by educational grants from GlaxoSmithKline, AstraZeneca, Sanofi Genzyme and Regeneron Pharmaceuticals.